Adial Pharmaceuticals, Inc.
ADIL
$0.68
$0.00520.77%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -10.07% | -13.01% | -22.39% | -39.12% | -37.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.27% | 5.53% | -18.26% | -39.39% | -39.87% |
| Operating Income | -20.27% | -5.53% | 18.26% | 39.39% | 39.87% |
| Income Before Tax | -88.48% | -70.40% | -37.70% | -6.25% | 37.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -88.48% | -70.40% | -37.70% | -6.25% | 37.74% |
| Earnings from Discontinued Operations | -- | -101.01% | -105.04% | 218.24% | 226.42% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -157.60% | -114.95% | -57.04% | 31.70% | 59.76% |
| EBIT | -20.27% | -5.53% | 18.26% | 39.39% | 39.87% |
| EBITDA | -20.28% | -5.53% | 18.26% | 39.38% | 39.85% |
| EPS Basic | 8.01% | 30.73% | 37.05% | 74.18% | 70.69% |
| Normalized Basic EPS | 49.59% | 65.28% | 61.60% | 61.78% | 53.29% |
| EPS Diluted | 8.10% | 30.78% | 37.08% | 74.19% | 70.66% |
| Normalized Diluted EPS | 49.59% | 65.28% | 61.60% | 61.78% | 53.29% |
| Average Basic Shares Outstanding | 239.95% | 248.05% | 150.67% | 85.80% | 44.12% |
| Average Diluted Shares Outstanding | 239.95% | 248.05% | 150.67% | 85.80% | 44.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
